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Summary
A cDNA clone encoding full-length human proliferating cell nuclear antigen (PCNA) was used
to generate a panel of in vitro translated labeled protein products with COOH-terminal deletions
and to construct a set of fusion proteins with COOH- and NH2-terminal deletions. A rabbit
antiserum raised against an NH2-terminal peptide, a well-characterized murine monoclonal
antibody (mAb), and 14 human lupus sera with autoantibody to PCNA were analyzed for their
reactivity with the constructs usingboth immunoprecipitation and immunoblotting techniques.
The rabbit antiserum reacted in immunoprecipitation and immunoblotting with constructs
containing the appropriate NH2-terminal sequence and mAb reacted with a sequence from the
midregion of PCNA. These experimentally induced antibodies also reacted with 15-mer synthetic
peptides in enzyme-linked immunosorbent assay (ELISA). In contrast, none of the lupus sera
reacted with synthetic peptides in ELISA. 9 of the 14 lupus sera also failed to react in Western
immunoblotting with any recombinant fusion protein, although they all immunoprecipitated
in vitro translatedfull-length protein. Four of the nine had variable patterns ofimmunoprecipitation
with shorter constructs. The remaining five lupus sera were able to immunoprecipitate translation
products as well as Western blot recombinant fusion proteins. From analysis of the patterns of
reactivity of human lupus sera, it was deduced that the apparent heterogeneity of human
autoantibodies to PCNA could be explained by immune response to highly conformational epitopes.
These observations demonstrate that there might be special features in "native" epitopes of intra-
nuclear antigens that are recognized by autoantibodies, and that these special features of native
epitopes might not be present in prepared antigen used for experimental immunization. These
features may be related to protein folding or to association of the antigen with other intranuclear
proteins or nucleic acids, as might occur with antigens that are components of subcellular particles.
Proliferating cell nuclear antigen (PCNA)l is the target
antigen for autoantibodies in the sera of ti3% ofpatients
with SLE (1, 2) . Although the autoantibodies occur in low
frequency in lupus, they have become valuable reagents for
the study of a key cellular component of the cell nucleus in
the late Gi and early S phase of the cell cycle (3-6). PCNA
has been identified as an auxiliary protein ofDNA polymerase
6 (7-9), a multisubunit nuclear particle that is required for
the replication of human (10, 11) and simian virus 40 DNA
(10, 12) and frog chromosomal DNA (13) .
The nature ofthe autoimmune response to PCNA has been
'Abbreviations used in this paper: FP, fusion protein; IPTG, isopropyl-B-
thio-galactopyranoside; IVP, in vitro protein products; PCNA, pro-
liferating cell nuclear antigen; RAPab, rabbit antipeptide antibody.
of interest and has been facilitated by extensive information
available concerning its molecular nature (7-9), identification
of its function (10-14), and cloning of DNA that encodes
the protein (15-17). Ogata et al. (18) analyzed the antige-
nicity of PCNA fragments generated by limited protease diges-
tion of purified rabbit PCNA. Reactivity of a rabbit poly-
clonal serum raised against an NH2-terminal peptide (rabbit
antipeptide antibody [RAPAb]), two murine mAbs (19) raised
against purified rabbit PCNA, and eight lupus sera with anti-
PCNA activity were analyzed. From this study, antigenic
domains reacting with lupus sera were shown to be located
in both the NH2- and COOH-terminal halves of PCNA,
whereas two murine mAbs (19A2 and 19F4) reacted with
a different domain located between the two lupus domains.
Further differences between monoclonal and lupus antibodies
have been demonstrated in functional assays, where autoan-
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DNA replication, but experimentally induced mAbs were
ineffective (13, 14).
In an attempt to further define the nature of the autoim-
mune response, we have takenamolecular approach. AcDNA
encoding full-length human PCNA was cloned and used to
synthesize a panel of radiolabeled in vitro translation prod-
ucts and a series of recombinant fusion proteins (FPs)
representing definedportions ofthePCNA polypeptide. Using
immunoprecipitationand immunoblotting techniques, reac-
tivities of RAPAb, mAb 19A2, and 14 lupus sera were ana-
lyzed with the aim of gaining more insight into the nature
ofantigenicdeterminants recognized by human autoantibodies.
Materials and Methods
SourceofAntibodies.
￿
RAPAbwasraised against a syntheticpep-
tide comprising amino acid residues 11-23 (18). The murine mAb
19A2 (IgM) was raised by immunization of BALB/c mice with
purified rabbit PCNA in CFA andhybridomas derived from spleen
cells (19) . Both these experimentally induced antibodies to PCNA
have been used previously and their cognateepitopes assigned to
differentStaphylococcus aureus V8 proteolytic fragments (18). In this
manner, the19A2 mAb hadbeen shownto recognize aproteolytic
fragment located in the midregion of PCNA separate from lupus
autoantibody epitopes. Lupus sera used in this study were from
ourlaboratory serumbank and from patients seen by Dr. Y Takasaki
(Juntendo University School of Medicine, Tokyo, Japan). These
sera were defined as containing antibodies to PCNA by immuno-
diffusionanalysis showing thepresence ofaprecipitatingantibody
with complete immunological identity with standard reference
serum, andby immunofluorescence showing nuclear staining that
varied with different phases of the cell cycle, but that was most
prominent in the Gt/S phase, as reported previously (1, 5, 6, 20, 21).
SyntheticPeptides.
￿
26 overlapping 15-mer peptides covering the
entire amino acid sequence of PCNA were synthesized by the
method of simultaneous multiple peptide synthesis, as described
previously (22). Allpeptides were synthesized as COOH-terminal
amides andanalyzed by reversephaseHPLC for purity, as reported
in a recent publication (23). The amino acid sequence of the in-
dividual peptides with overlapping residues are shownin Table 1.
Thepeptides were used forELISA, accordingto amethod described
previously (21). Briefly, 96-well ImmulonII plates (DynatechLabora-
tories, Alexandria, VA) were coated with thepeptides at a concen-
tration of0.4 ttgper well overnightandincubatedin abuffer con-
taining 10% gelatin in order to block nonspecific binding sites.
Lupus sera were tested at adilution of 1:200 in serum diluent con-
taining phosphatebuffer (pH 7.4), gelatin (10%), BSA(1 mg/ml),
and Tween-20 (0.05%). Peroxidase-labeled rabbit F(ab)2 anti-
humanIgGantibody (Dakopatts A/S, Copenhagen, Denmark) was
used diluted 1:200. For the mAb, a peroxidase-conjugated goat
anti-mouse IgG/IgM(CaltagLaboratories, SanFrancisco, CA) was
used diluted 1:15,000, and for the rabbit antiserum, a goat anti-
rabbit peroxidase conjugate(Caltag Laboratories) was used diluted
1:200. The mAbwasdiluted in serumdiluent described aboveand
tested at concentrations from 0.1 to 25 jig/ml. Therabbit antipep-
tide serum was tested at dilutions from 1:102 to 1:106.
CloningofPCNA.
￿
AcDNA encoding ratPCNA (15) was used
to screen a Xgt11 cDNA libraryconstructed from MOLT-4 human
lymphoblastoma mRNA. One phage, 1-4.3, containing a 1.2-kb
cDNA insert, was selected for further analysis. Theinsert was ex-
cisedusing partial EcoRldigestionand subdoned into theplasmid
420 Native Epitopes of Proliferating Cell Nuclear Antigen
Bluescript (Stratagene, La Jolla, CA).,Three subdones were iso-
latedthat were used in this work. Plasmids pHPCNA15 andpHP5.7
contained the entire 1-4.3 cDNA insert extending from 114 by
5' of the initiator ATG to a poly(A) tail; the two plasmids con-
tained theinsert in opposite orientations within thevector. Plasmid
pHPCNA10 contained a portion of the 1-4.3 cDNA insert ex-
tendingfrom the5' untranslated region to the internal EcoRl site
at codon 127. The identity of the cDNA as human PCNA was
verified by DNA sequencing of the termini of the clone and by
restriction mappingandcomparison with the sequence of Almen-
dral et al. (16).
In Vitro Transcription and Translation.
￿
Plasmids were linearized
by restriction digestionand used directly forin vitro transcription
using T7 RNA polymerase (Promega Biotec, Madison, WI) ac-
cording to the manufacturer's instructions. Plasmid pHPCNA15
was linearized with C1al, Asp718, and Bg1II for synthesis of full-
length, 211- and 150-aminoacid derivatives ofPCNA, respectively,
while pHPCNAIO was linearized with ClaI, EcoRV, and Ncol
to produce 128-, 85-, and 67-amino acid PCNA derivatives (see
Fig. 2). Transcripts were quantitated by absorption at 260nm and
were used withoutfurtherpurification forin vitrotranslation.Radio-
labeledin vitro protein products (IVPs) were synthesized by transla-
tion of T7 RNAs in anuclease-treated rabbit reticulocyte lysate (Pro-
mega Biotec, WI) according to themanufacturer's instructions using
I'S-methionine (NEN Research Products, Wilmington, DE). Pro-
tein synthesis was monitored by SDS-PAGE and fluorography.
Fusion Proteins.
￿
A series of eight plasmids expressing /3-gal/
PCNA FPswere constructed in Bluescript. PlasmidpHP5.7, con-
taining the PCNA cDNA in the same orientation as the ,0-ga-
lactosidase gene of Bluescript, was used to construct the expres-
sion derivatives. RE sites used for 5' deletions were BssHII,BspMI,
Ball, and StyI. RE sites for 3' deletions were BglII, EcoRI, and
Ball. Klenow fragment was used as needed to re-establish frame
(24). DHl bacteria were transformed with the plasmids, and FP
production was inducedby growing 5-ml bacterial cultures to an
ODsso of 0.5. Isopropyl-B-thio-galactopyranoside (IPIG) was
addedto a 10-mMfinalconcentration, and theculture wasincubated
overnight at 37°C. In the morning, the cultures were placed on
ice for 5 min, the bacteria pelleted, resuspended in 200 ul of 1x
Laemmli sample buffer, boiled for 5 min, run repeatedly through
a 25-gauge needle until nonviscous, and then stored at -20°C.
Immunoprecipitation.
￿
Labeled syntheticIVPs were immunopre-
cipitated using staphylococcal protein A-coated sepharose beads
(Pharmacia Fine Chemicals, Piscataway, NJ) adsorbed with anti-
body as previously described (20). Immunoprecipitated products
were run on 15% SDS-PAGE gels, andlabeled protein bandswere
visualized by fluorography.
Immunoblotting.
￿
Bacterial FP lysates from above (15 al) were
run on 15% SDS-PAGE, transferred to a nitrocellulose filter, and
reactivity of RAPAb, 19A2, andSLE sera with theFpswas tested
as previously described (18).Sera andantibodies were used at a1:200
dilution and were preabsorbed overnight at 4°C with nontrans-
formed bacterial lysate in a 100:1 ratio. Bacterial lysate was pre-
pared from DHlEscherichia coli containing Bluescript plasmid in-
duced overnight with IPM as above. A 100-ml culture was used
to make 5 ml of lysate.
Results
Reactivity with Synthetic Peptides in ELISA.
￿
mAb 19A2
reacted only with peptide 12, whichcovers amino acid residues
111-125, and not with anyoftheother 25 syntheticpeptides
(Fig. 1). The reaction of 19A2 was inhibited40-60% by pep-Underlined residues represent sequences overlapping with preceding or succeeding peptide.
tide 12 at a concentration of 1 !Ag/ml, and 95% inhibition
was obtained at 10 ug/ml. Other synthetic peptides were
not inhibitory. Biochemically purified rabbit PCNA at con-
centrations of 0.2-2.0 ,ttg/ml showed increasing degrees of
inhibitions ranging from 25 to 95%, respectively. Rabbit an-
tipeptide antibody reacted only with peptide 2 (Fig. 1), which
comprises amino acid residues 11-25 (immunizing peptide
was residues 11-23). Therefore, RAPAb reacted with the ex-
pected synthetic peptide, and 19A2 confirmed earlier studies
that the epitope was located in the mid-region ofPCNA (18,
21). In striking contrast to these results observed with ex-
perimentally induced antibodies, none of the 14 humanlupus
sera recognizedany of the 26 synthetic peptides. With some
of the peptides, there was a low noise background OD reading,
but the same background reading was observed with eight
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normal human sera tested as controls. The absence of specific
reactivity with synthetic peptides was not due to lack of
binding of peptides to ELISA plates, since presence of each
peptide on the plates was verified by direct colorimetric assay.
PCNA Clone.
￿
The restriction enzyme map for the 1.2-
kb cDNA insert in plasmid pHPCNA15 is shown in Fig.
2. It is in agreement with the restriction enzyme map of the
published sequence (16), except for a second Bg1II site lo-
cated -200 nucleotides distal to the stop codon in the 3' un-
translated region. Sequencing of the 5' end of pHPCNA15
showed it to begin at nucleotide 15 of the sequence reported
by Almendral et al. (16). This sequence was identical except
for the substitution of a cytosine for a thymidine at position
61 in the 5' untranslated region.
In Vitro Translation Products.
￿
Plasmids pHPCNA15 and
Table 1. PCNA 15-mer Synthetic Peptides
Peptide No. Amino acids Amino acid sequence
1 1-15 MFEARLVQ GS ILKKV
2 11-25 ILKKV LEALKDLINE
3 21-35 DL INEACWDI SSSGV
4 31-45 IS SSGV NLQSMDSSHV
5 41-55 DS SHV S L V QL TLRS E
6 51-65 TLRS E GFDTYRCDRN
7 61-75 RCDRNLAMGVNLTSM
8 71-85 NLTSMSKILKCAGNE
9 81-95 CAGNE DIITL RAEDN
10 91-105 RAEDNADT LA LVF EA
11 101-115 LVFEA PNQEKVSDYE
12 111-125 VSDYEMKLMD LDVEQ
13 121-135 LDVE LGI PE QEYSC
14 131-145 QEYSC VVKMP SGEFA
15 142-155 SGEFARIC RD LSHIG
16 151-165 LSHIGDAVVI SCAKD
17 161-175 SCAKD GVKFS ASGEL
18 171-185 ASGEL GNGNIKLS T
19 181-195 KLSQT SNV DK EEEAV
20 191-205 EEEAVTIEMNEPV L
21 201-215 EPV LTFALR YLNFF
22 211-225 YLNF F TKATP LSSTV
23 221-235 LSSTVTL SMS ADVPL
24 231-245 ADVPL VVEYK IADMG
25 241-255 I ADMG HL KYYLAPK I
26 247-261 LKYYLAPKIEDEEGS2.5
2.0
1.5
0
0
1.0
0.5
0.0
pHPCNA15
pHPCNA10
1 3 5 7 9 11 13 15 17 19 21 23 25
Peptide Number
Figure 1 .
￿
Reactivity in ELISA with 15-mer synthetic peptides.
RAPAb (O) reacted with peptide 2,, which contained the sequence of
the peptide used for immunization . No other peptides reacted with
RAPAb. The mouse monoclonal 19A2 (A) reacted only with peptide
12, a region of the PCNA protein that was inferred in previous
studies to contain the reactive site .
pHPCNA10 were linearized by restriction enzyme digestion
to produce templates for runoff in vitro transcription and
translation, as described in Materials and Methods . Six pro-
tein products were synthesized, ranging from the full-length
261-amino acid "native" PCNA to a 67-residue NH2-
terminal fragment (IVPs 1-6) (Fig. 2) . SDS-PAGE and fluorog-
raphy of the IVPs show protein products of approximately
36, 34, 20, 14, 10 and 8 kD in Fig. 3, lanes 1-6, (the 10-
and8-kD products ran with the dye front) . Additional lower
molecular weight polypeptides, designated IVP-F, were ob-
served in conjunction with thetwo largest translation prod-
ucts (IVPs 1 and 2 ; Fig. 3, lanes 1 and 2) . As these bands
were not present in controls and because oftheir lack of reac-
tivity with RAPAb and positive reactivity with some lupus
sera (see below), we interpreted them to beCOOH-terminal
fragments of PCNA .
FP Constructs . Eight FP cDNA constructs containing
different portions ofPCNA were prepared and expressed in
1-150
1-128
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IVPs
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1-261
IVP2
IVP3
IVP4
IVP5
￿
1-85
IVP6
￿
1 -67
FP1
￿
4-261
FP2
￿
38-261
FP3
￿
67-261
FP4
￿
99-261
FP8
￿
4-150
FP9
￿
4-128
FP11
￿
4-68
FP13
￿
67-150
Figure 2 .
￿
cDNA restriction enzyme map ofPCNA and the recom-
binant protein products derived by in vitro transcription and transla-
tion (IVPI-IVP6), and expression Fps used to map fragments reactive
with antibodies .
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Figure 3 .
￿
Fluorography in 15% SDS-PAGE of rabbit reticulocyte
transcription/translation products from synthetic RNAs corre-
sponding to constructs IVPs 1-6 in Fig . 2. M, molecular weight
markers ; A+, Poly(A)' mRNA translation ; B, without added
mRNA ; 1-6, IVPs 1-6 translation products. Some full-size PCNA is
seen in lanes 3 and 6 due to incomplete digestion of full-length
plasmid. Lower molecular weight products prominent in lane 1 are
presumed to be degradation products of full-length protein .
E. coli (diagrammed in Fig . 2) . Fps 1, 8, 9, and 11 were fused
at codon 4 of the human PCNA sequence with a 32-codon
fragment of0 galactosidase. Fps 8, 9, and 11 had progressive
3r-terminal deletions in the PCNA sequence and terminated
Figure 4 .
￿
Immunoprecipitation of IVPs with (A) RAPAb; (B)
mAb 19A2 . Lane H is labeled HeLa whole cell extract, and lanes 1-6
are translation products 1-6, respectively. (C and D) Western blotting
of fusion proteins with (C) RAPAb and (D) 19A2. Numbered lanes
correspond to the fusion proteins in Fig. 2 ; (D) DHl E. coli lysate;
(" molecular weight markers.Table 2.
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Immunoreactivity of IVPs and FPs of PCNA
Reactivity with antibodies
SLE II
￿
SLE III
￿
SLE IVA SLE IVB SLE I
Protein
￿
Amino acid
￿
mAb
product sequence RAPab 19A2 AI YK MI KU JO CR OK CA EB PT AK YO
IVP 1
￿
1-261
￿
+
￿
+
￿
+
￿
+
￿
+
￿
+
IVP 2
￿
1-211
￿
+
￿
+
￿
-
￿
-
￿
-
￿
-
IVP 3
￿
1-150
￿
+
￿
+
￿
-
￿
-
￿
-
￿
-
IVP 4
￿
1-128
￿
+
IVP 5
￿
1-85
￿
+
IVP 6
￿
1-67
￿
+
IVP-F" Unknown - -t
FP 1
￿
4-261
￿
+
￿
+
FP 2
￿
38-261
￿
-
￿
+
FP 3
￿
67-261
￿
-
￿
+
FP 4
￿
99-261
￿
-
￿
+
FP 8
￿
4-150
￿
+
￿
+
FP 9
￿
4-128
￿
+
￿
+
FP 11
￿
4-68
￿
+
￿
-
FP 13
￿
67-150
￿
-
￿
+
Results shown are immunoprecipitation for IVP and immunoblotting for FP.
' Lower molecular weight IVPs generated from full-length clone, possibly degradation products.
t Reactive only with the largest fragment of IVP-F.
with 6, 7, and 6 vector-derived codons, respectively. Fps 2,
3, 4, and 13 encoded proteins with progressive NH2-ter-
minal deletions in PCNA fused with a 30-residue NH2-
terminal leader derived froma galactosidase (Fig. 2) . FP 13
encoded both NH2- and COOH-terminal deletions. DNA
sequencing across the deletion sites of Fps 1 and 4 confirmed
the predicted nucleotide sequences.
Immunoprecipitation and Immunoblotting of RAPAb and
19A2. RAPAb, which was raised against synthetic peptide
11-23 ofPCNA, immunoprecipitated all six IVPs, as expected
(Fig. 4 A). Note that the lower molecular weight proteins
detectable in Fig. 3, lane 1 (IVP-F) were not immunoprecipi-
tatedby RAPAb, suggesting that these lowermolecular weight
proteins lack this NH2-terminal sequence. mAb 19A2 im-
munoprecipitated IVPs 1, 2, and 3, as expected, but not the
shorter protein constructs (Fig. 4 B). Surprisingly, IVP 4,
which consists ofresidues 1-128 and therefore contained the
region 111-125, was not immunoprecipitated by 19A2 (Fig.
4 B). In addition to precipitation of full-length IVP 1, 19A2
precipitated a product that migratedjust below the full-length
construct (Figure 4 B, lane 1).
In Western blotting, RAPAb was reactive with Fps 1, 8,
9, and 11 (Fig. 4 C), all of which contained amino acids 11-23,
the peptide that was used in immunization. mAb 19A2 was
reactive with Fps 1-4, 8, 9, and 13, but not with FP 11 (Fig.
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NE FL
4 D). These findings are also consistent with the observa-
tions showing that 19A2 reacted in a highly specific manner
with peptide 111-125. It can also be observed from Fig. 4
D that 19A2 was reactive with many lowermolecular weight
bands of several Fps, suggesting that these products contained
epitopic determinants present in peptide 111-125.
Reactivity ofLupusSera.
￿
Specific patterns of reactivity of
lupus sera with in vitro translated products and recombinant
Fps allowed the autoantisera to be classified into four groups
(Table 2). The first group of five sera immunoprecipitated
the full-length native PCNA construct only and were not
reactive with any of the shorter in vitro translated products
(Fig. 5 A). Another feature of group 1 sera was that they
were totally nonreactive in Western blots with any of the
fusion proteins. The second group of four sera (SLE II) all
immunoprecipitated full-length construct (IVP 1) but showed
variable reactivity with the protein constructs containing
COOH-terminal deletions (IVPs 2-5; Fig. 5 B). They were
also nonreactive with the lower molecular weight fragments
ofIVP 1 (IVPF). The immunoprecipitation pattern of serum
O.K. in this group is depicted in Fig. 5 B, showing immu-
noprecipitation of full-length PCNA in lanes 1 and 3 (the
latter due to residual undigested full-length cDNA) and IVPs
4 and 5 in lanes 4 and S, respectively. There was some vari-
ability in this group since serum C.R. was reactive with allof the four longer constructs, while the three remaining sera,
O.K ., C.A ., andE.B., were not reactive with the two inter-
mediate constructs IVP 2 and 3, but were reactive with the
full-length and two shorter constructs, IVP 4 and 5 . Like
the group I sera, group II sera uniformly failed to react with
bacterial Fps in Western blots (Fig. 6 A) . The third group
of lupus sera represented by PT, A.K ., and Y.O . immuno-
precipitated full-length protein (IVP 1) and degradation prod-
ucts, but they did not immunoprecipitate any ofthe000H-
terminal deleted translation products (Fig . 6 C) . In contrast
to groups 1 and 2, these sera were highly reactive in Western
blots with the NH2-terminal deletion Fps (Fps 1-4) and had
variable reactivity with the other Fps, 8, 9, and 13 (Fig. 6
B) . None of the group III sera reacted with FP 11, residues
4-68 (Fig. 6 B, and Table 2) . An example of reactivity o£
group III sera is depicted in Fig. 6 B for A.K. serum .
Finally, there weretwo sera that appeared to combine the
features ofcapability to immunoprecipitate multiple transla-
tion products as well as immunoblot Fps . Serum N.E .,
classified asSLE IVA, immunoprecipitated IVPs 1-3, but were
unable to react with IVPs 4, 5, and 6 (Fig. 5D) . In Western
blotting, this serum was reactive with all Fps, except for Fps
11 and 13 (Fig . 6 C) . It was noted that serumN.E . reacted
with FP-9 (residues 4-128) but did not precipitate IVP 4
(residues 1-128) . Serum F.L ., classified as SLE IVB, precipi-
tated the full-length construct and IVPs 4 and 5 (Fig. 5 E),
and in Western blots reacted with all Fps exceptFP 11 (residues
4-67), as depicted in Fig. 6 D . The background staining
depicted in Fig. 6, C and D was high and could not be re-
moved by repeated adsorptions with nontransformed E . coli
lysates . However, repeat experiments confirmed the above
findings with the sera.
424
￿
Native Epitopes of Proliferating
Discussion
Figure 5 .
￿
Immunoprecipitation
of IVPs with lupus sera. (A)
Representative group I serum AI ;
(B) representative group lI serum
OK ; (C) representative group III
serum AK ; (D) representative
group IVA serum NE ; and (E)
representative group IVB serum
FL . Lane H is labeled HeLa
whole cell extract, lane B is
blank, where no serum was used
in immunoprecipitation of IVP1.
Lanes 1 and 6 are translation
products IVPs 1-6, respectively.
Immunoprecipitation of sponta-
neous degradation fragments of
full-length protein (lane 1) is ob-
served in C, D, and E.
We have developed three sets of reagents for examination
of the immunologically reactive structures ofPCNA : cDNA
derived in vitro translation products, bacterial Fps, and a panel
of synthetic 15-mer peptides . Application of these reagents
using the complementary techniques ofimmunoprecipitation,
immunoblotting, andELISA has allowed us to probe the reac-
tivities ofboth primary and tertiary structure-dependent epi-
topes . This approach was validated using the rabbit anti-peptide
antibody raised against residues 11-23 of PCNA . By sub-
traction analysis of the results obtained using cDNAderived
IVPs and Fps, it was possible to map the RAPAb epitope
to a region between residues 4 and 38 ofPCNA, which con-
formed to the result obtained byELISA . Similarly, the reac-
tivity ofmAb 19A2 was localized to a region between residues
68 and 128, consistent with previous S. aureus V8-induced
proteolytic peptide mapping studies. The epitope was nar-
rowed down to region 111-125 of PCNA by ELISA using
synthetic peptides . These results demonstrate both the reso-
lution of this approach and the sensitivity of the method for
detection of primary sequence epitopes.
Several interesting observations emerge with analysis of the
reactivity of lupus sera. A substantial number (9 of 14) did
not blot recombinant Fps, this feature being characteristic
of sera in groups I and II . Because sera in groups II, III, IVA,
and IVB showed different reactivity with certain defined sub-
fragments, it was possible to construct an epitope map by
subtraction analysis, as shown in Fig. 7 . Three sera in group
11 (Fig. 7, top left) were able to immunoprecipitate IVP5 (1-85)
but not IVP6 (1-67), indicating that the sequence between
residues 67 and 85 is an important component of the epi-
tope. IVP4 retained reactivity, as did full-length PCNA, but
Cell Nuclear Antigensurprisingly, IVPs 2 and 3 were not reactive even though IVPs
4 and 5 are a subset of sequences present in the larger pro-
teins . This implies that the additional residues in IVPs 2 and
3 interfere with the reactivity of the region 67-85 . Reactivity,
however, is restored in full-length PCNA (IVP-1), implying
two possibilities. One is that the additional sequence at the
COOH terminus in some way counteracts the interference
with the reactivity of region 67-85 seen with IVPs 2 and
3 . The other is that there may be a second antibody popula-
tion that is dependent on the presence of the COOH ter-
minus. Serum C.R . in this group showed a reactivity that
could be explained by recognition of an epitope bound by
residues 86-128, with no dependence on theCOON-terminal
212-261 peptide, since it is reactive with the constructs IVPs
II and III lacking this region .
The sera in group III (Fig . 7, top right) reacted only in
Western blots and were not found to immunoprecipitate less
than full-length translation products . Sera A.K . and YO.
blotted all NHa-terminal deletion products to FP 4, demon-
strating that the epitope was present downstream from res-
idue 99 . The smallest COOH-terminal deletion that retained
reactivity extended to residue 128 . Thus, the boundaries of
the epitope must lie between residues 99 and 128 . Serum PT
would appear to require additional residues, extending its epi-
tope from 99 to 150. These sera were unable to immunopre-
cipitateCOON-terminal deletion products even though these
polypeptides possessed the sequences shown by Western blot
to be required for immunoreactivity. This suggests that the
epitope is sensitive to conformational changes inducedby these
restriction enzyme-engineered deletions . However, the spon-
taneous degradation fragments of full-length PCNA (IVRF)
are precipitated by these sera . It has been observed that pro-
teolytic enzymes cleave between structured domains separated
by flexible polypeptide fragments (25, 26) . This might explain
features observed by us previously that proteolytic digestion
ofnuclear antigens such as SS-B/La and PCNA result in degra-
dation fragments, many of which retained reactivity with
autoantibodies (18, 27) . In the case of SS-B antigen, diges-
tion with S. aureusV8 resulted in a fragment of 28 kD, which
retained reactivity with autoantibody as well asRNAbinding
property (28) . It is obvious that PCNA fragments generated
by the use of restriction enzyme cleavage of cDNA result
in truncated protein products that do not correspond to the
natural structural domains of PCNA .
The sera in groups IVA and IVB appeared to combine the
properties of sera in group II (for immunoprecipitation) and
group III (for Western blotting) . Serum N.E ., classified as
group IVA (Fig. 7, bottom left), was reactive in Western blots
like the group III sera, recognizing the peptide sequence
99-128 . In immunoprecipitation, it appeared to require the
region 128-150 to express the epitope . Serum F .L . of group
IVB (Fig. 7, bottom right) was similar to group III and group
IVA serum in Western blotting reactivity, but for immuno-
precipitation, residues 68-128 and COON-terminal 212-261
were required like the group II sera .
The differences between experimentally induced antibodies
to PCNA and human autoantibodies were striking . Rabbit
antipeptide antibody and monoclonal 19A2 were reactive with
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Figure 6 .
￿
Western blots of FPs. Absence of reactivity with FP frag-
ments from group II SLE sera is demonstrated in A . The reactivity of
SLE group III sera (AK) is shown in B; group IVA (NE) in C; and
group IVB (FL) in frame D. Nontransformed DHI E. colt lysate is
shown in lane D . The high backgrounds in C and D were character-
istic of the sera and could not be removed with repeated absorptions
with nontransformed E. coli lysate.
synthetic peptides, and in a consistent manner with defined
subfragments ofPCNA in immunoprecipitation and Western
blotting. This is in marked contrast to lupus autoantibodies,
which were completely nonreactive with synthetic peptides .
The peptides were linear sequences of 15 residues, but with
amino acid sequences overlapping in such a manner that any
combination of six continuous residues in PCNA would be
represented in this battery ofsynthetic peptides. The absence
ofreactivity indicates that the epitopes recognized by lupus
sera are not present in these peptides. This observation cou-
pled with the inability of the majority (9/14) of lupus sera
to immunoblot recombinant Fps suggest that the epitopes
recognized by certain human autoantibodies are comprised
of higher ordered conformational structures not representedH
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in the synthetic peptides. This type of conformational struc-
ture may be formed by amino acid residues from two or more
regions of the molecule that are brought into proximity with
one another by protein folding. Geysen et al. (29) have ana-
lyzed the reactivityof a mAb directed against a discontinuous
antigenic determinant in foot and mouth disease virus. They
showed that a linear hexapeptide with the appropriate
stereochemistry can mimic an epitope that was deduced to.
be derived from three separate regions of the antigen. It is
possible that none of the peptides of PCNA that were syn-
thesized contain the correct sequence, if the epitope was of
such a nature.
The differences observed between mAbs and human au-
toantibodies to PCNA were not restrictedto the mAb 19A2
reported here. In separate studies where reactivity with syn-
thetic peptides in ELISA was the only assayexamined, a second
Figure 7.
￿
Epitope mapping of reactive regions in PCNA protein deduced by subtraction analysis of data derived from immunoprecipitation and
Western blotting. SLE group II (top left) sera were reactive only by immunoprecipitation, and the regions necessary for reactivity could be localized
to the stippled area for O.K., C.A., and E.B., and the hatched area for serum C.R. SLE group III (top right) sera were nonreactive with truncated
translation products, but were reactive with Fps, and the regions necessary for reactivity were mapped to the shaded areas. The stippled area repre-
sented the reactivity of sera A.K. and Y.O. (Bottom left) The reactions with translation products as well as Fps deduced to be reactive with SLE
group IVA (NE). (Bottom right) The reactivity of group IVB serum (FL).
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mAb, 19F4, was also reactive with these synthetic peptides.
Differences between certain experimentally induced antibodies
and spontaneously occurring human autoantibodies have also
been demonstrated in a study in which five murine mAbs
to SS-B/La, another nuclear autoantigen in lupus, were com-
pared with spontaneously occurring autoantibodies from pa-
tients (30). It was observed that the murine mAbs had different
reaction patterns from human autoantibodies, including the
observation that autoantibodies were reacting with epitopes
that were more highly conserved across species, while the
monoclonals were restrictedin theircrossreactivity. It might
be important to consider that although the immune systems
in rabbits and mice (for experimental antibodies), and in pa-
tients (for autoantibodies), are responding to the same im-
munogen, the immunogen could be presented in different
structuralforms. It is unlikely that the patient's immune system
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FP13 67-150 FP13 67-150is encountering purified PCNA protein by itself, as in ex-
perimentalimmunization. There is much evidence that many
of the intranuclear antigens are subcomponents of multi-
molecular particles (3, 31), and it is likely that the immune
system in patients is encountering PCNA in the context of
its association with otherproteins or nucleic acids. The im-
munogen in patients appears to be subcellular particles, many
of which are engaged in important or essential cellular func-
tions (3, 32-38). Some observations indicate that epitopes
of autoantigens in these particles might represent the active
sites or functional regions, since autoantibodies are capable
of inhibiting function, as in the case of PCNA (12-14),
threonyl-tRNA synthetase (33), and other intracellular an-
tigens (34-36, 38).
Autoantibodies to nuclear antigens have proved to be valu-
able reagents for cloning ofDNA that encode these antigens.
As a result, many cDNA clones have been generated, and
a major direction of research in the field has been to make
use of these clones and their protein products to identify the
epitopes recognizedby autoantibodies. This type of "epitope
mapping" has been performed for centromere protein B (39),
an autoantigen in patients with a subset of scleroderma, the
A protein of small nuclear ribonucleoprotein particles (40),
and a 68/70-kD protein that is an autoantigen in patients
with mixed connective tissue disease (40-42), the SS-B/La
antigen in patients with Sjogren's syndrome and lupus (43-46),
the Ku or p70 DNA binding protein antigen in patients with
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